AstraZeneca Denies Ongoing Talks for Bristol Myers Squibb Takeover After Share Plunge

AstraZeneca is reportedly no longer contemplating a takeover of its US rival, Bristol Myers Squibb (BMS), a move that would have created a pharmaceutical colossus valued at approximately $400 billion (£300 billion).

On Monday, AstraZeneca's shares experienced a significant decline, plunging 9%, following a report by the Financial Times detailing preliminary discussions between the two companies. However, on Wednesday, Reuters indicated that no ongoing discussions are currently taking place, leading to a partial recovery in AstraZeneca's share price.

Neither company has officially communicated with its shareholders regarding the situation, making it difficult to ascertain the nature of the talks – whether they were a brief, exploratory "what if?" scenario or a more substantial proposal that has since been terminated, potentially due to a lack of enthusiasm from AstraZeneca's shareholders.

The proposed deal appeared unusual for several reasons. AstraZeneca has achieved considerable success under the leadership of chief executive Sir Pascal Soriot over the past 14 years by prioritizing investment in its laboratory innovations for long-term growth, rather than engaging in debt-financed takeovers focused on short-term cost reductions. Soriot has expressed strong confidence in meeting AstraZeneca's revenue target of $80 billion by 2030, suggesting no immediate need to deviate from this established strategy. Furthermore, Bristol Myers Squibb faces revenue challenges in the coming years as a major blockbuster cancer treatment approaches patent expiration.

Despite these points, potential counterarguments exist. Both companies have a strong presence in the oncology sector, presenting an opportunity to establish prolonged dominance if competition regulators could be appeased. The synergy between the two firms might have offered greater or more easily achievable cost savings than typically expected. It is also possible that Soriot identified untapped potential in BMS's drug pipeline or saw an opportunity to accelerate AstraZeneca's goal of generating half its revenue from the US market, the largest and most profitable for pharmaceutical firms, where it currently stands at 43%.

Regardless of the specifics, Soriot is urged to provide clarity on whether significant "mega-deals" are a potential component of AstraZeneca's future strategy. While maintaining a "no comment" stance on individual takeover rumors is understandable, most AstraZeneca shareholders likely assume they are invested in a company that does not pursue financially precarious, large-scale acquisitions. Although AstraZeneca's acquisition of rare diseases specialist Alexion in 2021 for $39 billion was substantial, it was not on the scale of BMS's $133 billion valuation, and the primary rationale for that deal was to foster innovation.